Last reviewed · How we verify
Gemcitabine-Cisplatin chemotherapy
Gemcitabine and cisplatin work synergistically to damage cancer cell DNA and prevent its repair, leading to cell death.
Gemcitabine and cisplatin work synergistically to damage cancer cell DNA and prevent its repair, leading to cell death. Used for Non-small cell lung cancer, Ovarian cancer, Bladder cancer.
At a glance
| Generic name | Gemcitabine-Cisplatin chemotherapy |
|---|---|
| Also known as | GP chemotherapy |
| Sponsor | Simcere Pharmaceutical Co., Ltd |
| Drug class | Chemotherapy combination (nucleoside analog + platinum agent) |
| Target | DNA (multiple targets including ribonucleotide reductase inhibition and DNA cross-linking) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Gemcitabine is a nucleoside analog that inhibits ribonucleotide reductase and gets incorporated into DNA, causing chain termination and apoptosis. Cisplatin is a platinum-based alkylating agent that forms DNA cross-links, preventing replication and transcription. Together, they provide complementary cytotoxic mechanisms with enhanced efficacy against rapidly dividing cancer cells.
Approved indications
- Non-small cell lung cancer
- Ovarian cancer
- Bladder cancer
- Pancreatic cancer
- Breast cancer
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia, anemia)
- Nausea and vomiting
- Nephrotoxicity
- Ototoxicity
- Peripheral neuropathy
- Alopecia
- Mucositis
- Fatigue
Key clinical trials
- Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer (PHASE1)
- Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) (PHASE2, PHASE3)
- A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) (PHASE2)
- MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma (PHASE2)
- Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial (PHASE2)
- A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer (PHASE2)
- Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer (PHASE2, PHASE3)
- A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: